ISU

We are thriving as a specialized biomedicine company that saves precious lives by developing rare disease therapeutics based on genetic recombination technology.

Founded in 2001, ISU Abxis is a leading company in the development of biomedicines based on genetic recombination technology. Especially, we have concentrated our capabilities on rare disease therapeutics development that shows high market growth, thus we have achieved results to become the only company in Korea that developed three kinds of biomedicines.

In 2007, we launched ‘Clotinab’, the first domestic antithrombotic antibody therapeutics, followed by ‘Abcertin’, the Guacher disease therapeutics and ‘Fabagal’, the Fabry disease therapeutics, in 2013 and 2014, respectively. We are now concentrating on developing new biomedicines including therapeutics for incurable cancer, hemophilia and paroxysmal nocturnal hemoglobinuria, Not only consistent investment, but also the excellent people and facilities are the driving forces to achieve outstanding results. More than 45% of the manpower is composed of researchers who have masters’ or doctors’ degree and we have a world-class cGMP bio pharmaceutical facility established. Through proactive new medicine development, cooperation with domestic pharmaceutical companies and overseas market development, we will become the rare disease therapeutic company that represents Korea.